Perhaps the simultaneous, combinatorial effects on p53 and NF-κB that are core mechanisms in the anti-tumor effect of CBL0137 provide an even more compelling rationale to clinically test this agent, especially against DPM. The gene discussed is TP53; the disease is neoplasm.